123 related articles for article (PubMed ID: 38054250)
1. Highly photoactive Ir(III)-Pt(IV) heterometallic conjugates for anticancer therapy.
Hu W; Liu R; Zheng K; Wang Z
Chem Commun (Camb); 2024 Jan; 60(4):388-391. PubMed ID: 38054250
[TBL] [Abstract][Full Text] [Related]
2. Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs.
Shi H; Romero-Canelón I; Hreusova M; Novakova O; Venkatesh V; Habtemariam A; Clarkson GJ; Song JI; Brabec V; Sadler PJ
Inorg Chem; 2018 Nov; 57(22):14409-14420. PubMed ID: 30365308
[TBL] [Abstract][Full Text] [Related]
3. Photocytotoxic Pt(iv) complexes as prospective anticancer agents.
Canil G; Braccini S; Marzo T; Marchetti L; Pratesi A; Biver T; Funaioli T; Chiellini F; Hoeschele JD; Gabbiani C
Dalton Trans; 2019 Aug; 48(29):10933-10944. PubMed ID: 31165118
[TBL] [Abstract][Full Text] [Related]
4. Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.
Henke H; Kryeziu K; Banfić J; Theiner S; Körner W; Brüggemann O; Berger W; Keppler BK; Heffeter P; Teasdale I
Macromol Biosci; 2016 Aug; 16(8):1239-1249. PubMed ID: 27169668
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.
Zajac J; Kostrhunova H; Novohradsky V; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2016 Mar; 156():89-97. PubMed ID: 26780576
[TBL] [Abstract][Full Text] [Related]
6. Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects.
Tabrizi L; Thompson K; Mnich K; Chintha C; Gorman AM; Morrison L; Luessing J; Lowndes NF; Dockery P; Samali A; Erxleben A
Mol Pharm; 2020 Aug; 17(8):3009-3023. PubMed ID: 32628022
[TBL] [Abstract][Full Text] [Related]
7. Dual-platination and induced oxidation of uridine by a photoactivatable diazido Pt(IV) anticancer prodrug.
Gao F; Zhang J; Wu X; Zhao Y; Wang F; Wu K
Dalton Trans; 2022 Aug; 51(31):11834-11839. PubMed ID: 35866478
[TBL] [Abstract][Full Text] [Related]
8. Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands.
Savino S; Gandin V; Hoeschele JD; Marzano C; Natile G; Margiotta N
Dalton Trans; 2018 May; 47(21):7144-7158. PubMed ID: 29766157
[TBL] [Abstract][Full Text] [Related]
9. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.
Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2014 Nov; 140():72-9. PubMed ID: 25063910
[TBL] [Abstract][Full Text] [Related]
10. Unexpected photoactivation pathways in a folate-receptor-targeted
Gandioso A; Rovira A; Shi H; Sadler PJ; Marchán V
Dalton Trans; 2020 Sep; 49(34):11828-11834. PubMed ID: 32815971
[TBL] [Abstract][Full Text] [Related]
11. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug.
Reshetnikov V; Arkhypov A; Julakanti PR; Mokhir A
Dalton Trans; 2018 May; 47(19):6679-6682. PubMed ID: 29708261
[TBL] [Abstract][Full Text] [Related]
12. Photoactivatable diazido Pt(IV) anticancer complex can bind to and oxidize all four nucleosides.
Cheng Y; Zhang J; Wu K; Gao F; Cheng Y; Zou T; Wu X; Zhao Y; Wang F
Dalton Trans; 2020 Dec; 49(47):17157-17163. PubMed ID: 33244530
[TBL] [Abstract][Full Text] [Related]
13. Human transport protein carrier for controlled photoactivation of antitumor prodrug and real-time intracellular tumor imaging.
Li X; Mu J; Liu F; Tan EW; Khezri B; Webster RD; Yeow EK; Xing B
Bioconjug Chem; 2015 May; 26(5):955-61. PubMed ID: 25938732
[TBL] [Abstract][Full Text] [Related]
14. Adenine-adenine, adenine-cytosine and cytosine-cytosine intrastrand crosslinks induced by a photoactivatable Pt(IV) anticancer prodrug.
Lin J; Huang J; Zhang J; Qin X; Ma Z; Wu X; Wang F; Zhao Y; Wu K
Dalton Trans; 2023 Dec; 53(1):292-298. PubMed ID: 38047479
[TBL] [Abstract][Full Text] [Related]
15. An integrin-targeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies.
Gandioso A; Shaili E; Massaguer A; Artigas G; González-Cantó A; Woods JA; Sadler PJ; Marchán V
Chem Commun (Camb); 2015 Jun; 51(44):9169-72. PubMed ID: 25947177
[TBL] [Abstract][Full Text] [Related]
16. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
Ravera M; Perin E; Gabano E; Zanellato I; Panzarasa G; Sparnacci K; Laus M; Osella D
J Inorg Biochem; 2015 Oct; 151():132-42. PubMed ID: 26277416
[TBL] [Abstract][Full Text] [Related]
17. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
Xiao H; Noble GT; Stefanick JF; Qi R; Kiziltepe T; Jing X; Bilgicer B
J Control Release; 2014 Jan; 173():11-7. PubMed ID: 24511610
[TBL] [Abstract][Full Text] [Related]
18. New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells.
Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
Biochem Pharmacol; 2015 Jun; 95(3):133-44. PubMed ID: 25888926
[TBL] [Abstract][Full Text] [Related]
19. Reaction of human telomeric unit TTAGGG and a photoactivatable Pt(IV) anticancer prodrug.
Lin J; Zhang J; Ma Z; Wu X; Wang F; Zhao Y; Wu K; Liu Y
Dalton Trans; 2023 Aug; 52(34):12057-12066. PubMed ID: 37581306
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional Iridium(III)-Platinum(IV) Conjugates as Potent Anticancer Theranostic Agents.
Gupta A; Pandey AK; Mondal T; Bhattacharya J; Sasmal PK
J Med Chem; 2023 Jul; 66(13):8687-8704. PubMed ID: 37387570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
